Immunology and Inflammatory Biotech Company Bambusa (BBTX.US) Sets IPO Price at $15-$17 Per Share, Plans to Raise $150 Millions

According to Golden Ten Data APP, Bambusa Therapeutics, a biotechnology company focusing on immunology and inflammation, announced the terms of its initial public offering (IPO) on Monday. The company plans to raise $150 million by issuing 9.4 million shares at a price range of $15 to $17 per share. Based on the midpoint of the proposed price range, Bambusa Therapeutics’ fully diluted market value will reach $837 million. The company plans to list on Nasdaq under the ticker symbol “BBTX.” The IPO is expected to be priced during the week of October 26, 2026.